Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana

Vaccine

Volumn 30, Issue 15, 2012, Pages 2582-2587

  Abbott, Collette ^a   Tiede, Benjamin ^a   Armah, George ^b   Mahmoud, Adel ^a  

^a PRINCETON UNIVERSITY   (United States)

^b University of Ghana   (Ghana)

Author keywords

Cost effectiveness; Ghana; Rotavirus vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GHANA; HEALTH CARE COST; HUMAN; INFECTIOUS DIARRHEA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SENSITIVITY ANALYSIS; VACCINATION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DIARRHEA; FEMALE; GASTROENTERITIS; GHANA; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 84858280812     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.076     Document Type: Article

References (50)

1. Kaler S.G. Diseases of poverty with high mortality in infants and children: malaria, measles, lower respiratory infections, and diarrheal illnesses. Ann N Y Acad Sci 2008, 1136:28-31.
2. Black R.E., Cousens S., Johnson H.L., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375(9730):1969-1987.
3. Steele A.D., Peenze I., de Beer M.C., et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine 2003, 21(5-6):354-360.
4. O'Ryan M., Perez-Schael I., Mamani N., et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J 2001, 20(7):685-693.
5. Parashar U.D., Gibson C.J., Bresse J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12(2):304-306.
6. Glass R.I., Parashar U.D., Bresee J.S., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006, 368(9532):323-332.
7. Podewils L.J., Mintz E.D., Nataro J.P., Parashar U.D. Acute: infectious diarrhea among children in developing countries. Semin Pediatr Infect Dis 2004, 15(3):155-168.
8. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9(5):565-572.
9. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
10. Vesikari T., Matson D.O., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
11. Glass R.I., Parashar U.D. The promise of new rotavirus vaccines. N Engl J Med 2006, 354(1):75-77.
12. Glass R.I., Patel M., Parashar U. Lessons from the US rotavirus vaccination program. JAMA 2011, 306(15):1701-1702.
13. Danchin M.H., Bines J.E. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl J Med 2009, 361(20):1919-1921.
14. Armah G.E., Sow S.O., Breiman R.F., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):606-614.
15. Madhi S.A., Cunliffe N.A., Steele D., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
16. World Health Organization WHS report of Ghana 2009, World Health Organization, Geneva.
17. Armah G.E., Steele A.D., Binka F.N., et al. Changing patterns of rotavirus genotypes in Ghana: emergence of human rotavirus G9 as a major cause of diarrhea in children. J Clin Microbiol 2003, 41(6):2317-2322.
18. African Rotavirus Network African rotavirus surveillance newsletter 2008, African Rotavirus Network, p. 1-3.
19. Binka F.N., Anto F.K., Oduro A.R., et al. Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. Trop Med Int Health 2003, 8(9):840-846.
20. Reither K., Ignatius R., Weitzel T., et al. Acute childhood diarrhoea in northern Ghana: epidemiological, clinical and microbiological characteristics. BMC Infect Dis 2007, 7:104.
21. Witter S., Garshong B. Something old or something new? Social health insurance in Ghana. BMC Int Health Hum Rights 2009, 9:20.
22. World Health Organization/UNICEF. Review of national immunization coverage, 1980-2008: Ghana; July 2009.
23. Merck & Co. Inc. Merck Commends GAVI Alliance on Continued Efforts to Improve Acces: Merk Offers Further Commitment to Sustainable Vaccine Access; 2011.
24. PATH/GAVI Alliance. Rotavirus Vaccine Program. Introduction of rotavirus vaccine with support from the GAVI Alliance: information to assist the national decision-making and application process, vol. 2010; 2008.
25. Rheingans R.D., Constenla D., Antil L., Innis B.L., Breuer T. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007, 21(4):192-204.
26. Rheingans R.D., Antil L., Dreibelbis R., Podewils L.J., Bresee J.S., Parashar U.D. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009, 200(Suppl 1):S16-S27.
27. Edejer T.T.-T., World Health Organization Making choices in health: WHO guide to cost-effectiveness analysis 2003, World Health Organization, Geneva, p. xiii, 312 [318 p].
28. Ghana Statistical Service and Ghana Health Service. Demographic and Health Surveys, Ghana: Standard DHS, 2003 - Final Report; 2003.
29. World Health Organization. Child rotavirus deaths 2004; March 2006.
30. Pitzer V.E., Viboud C., Simonsen L., et al. Demographic variability: vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009, 325(5938):290-294.
31. Liddle J.L., Burgess M.A., Gilbert G.L., et al. Rotavirus gastroenteritis: impact on young children, their families and the health care system. Med J Aust 1997, 167(6):304-307.
32. Marsella M., Raimondi L., Bergamini M., et al. Epidemiology of rotavirus-associated hospital admissions in the province of Ferrara, Italy. Eur J Pediatr 2009, 168(12):1423-1427.
33. Walker D.G., Hutubessy R., Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28(11):2356-2359.
34. World Health Organization Ghana: estimates of unit costs for patient services for Ghana 2010, WHO, Geneva.
35. Aikins M., Armah G., Akazili J., Hodgson A. Hospital health care cost of diarrheal disease in Northern Ghana. J Infect Dis 2010, 202(Suppl):S126-S130.
36. Berry S.A., Johns B., Shih C., Berry A.A., Walker D.G. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010, 202(Suppl):S108-S115.
37. Arvay M.L., Curns A.T., Terp S., et al. How much could rotavirus vaccines reduce diarrhea-associated mortality in northern Ghana? A model to assess impact. J Infect Dis 2009, 200 Suppl 1:S85-S91.
38. Staat M.A., Payne D.C., Donauer S., et al. Effectiveness of pentavalent rotavirus vaccine against severe diarrhea. Pediatrics 2011, 128(2):e267-e275.
39. World Health Organization Macroeconomics and health: investing in health for economic development 2001, World Health Organization, Geneva.
40. Brouwer W.B., Niessen L.W., Postma M.J., Rutten F.F. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005, 331(7514):446-448.
41. Gravelle H., Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001, 10(7):587-599.
42. Wolfson L.J., Gasse F., Lee-Martin S.P., et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy: 2006-2015. Bull World Health Organ 2008, 86(1):27-39.
43. Secretariat G.A.V.I Accelerated Vaccine Introduction (AVI) Progress Report. GAVI Alliance Board Meeting 2010, 1-10.
44. GAVI Donors commit vaccine funding to achieve historic milestone in global health: GAVI Alliance poised to immunise more than 250 million children in developing countries by 2015. Pledging conference 2011.
45. World economic outlook database 2009, International Monetary Fund, GDP Per Capita.
46. Postma M.J., Jit M., Rozenbaum M.H., Standaert B., Tu H.A., Hutubessy R.C. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Med 2011, 9:84.
47. Kim S.Y., Goldie S.J., Salomon J.A. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009, 9:29.
48. Fischer T.K., Anh D.D., Antil L., et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005, 192(10):1720-1726.
49. Kim S.Y., Sweet S., Chang J., Goldie S.J. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis 2011, 11:174.
50. Tu H.A., Rozenbaum M.H., Coyte P.C., Li S.C., Woerdenbag H.J., Postma M.J. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries. Vaccine 2011.